Colección SciELO Chile

Departamento Gestión de Conocimiento, Monitoreo y Prospección
Consultas o comentarios: productividad@anid.cl
Búsqueda Publicación
Búsqueda por Tema Título, Abstract y Keywords



Breast cancer management in middle-resource countries (MRCs): Consensus statement from the Breast Health Global Initiative
Indexado
WoS WOS:000290194000003
Scopus SCOPUS_ID:79953065840
DOI 10.1016/J.BREAST.2011.02.015
Año 2011
Tipo artículo de investigación

Citas Totales

Autores Afiliación Chile

Instituciones Chile

% Participación
Internacional

Autores
Afiliación Extranjera

Instituciones
Extranjeras


Abstract



In middle resource countries (MRCs), cancer control programs are becoming a priority as the pattern of disease shifts from infectious diseases to non-communicable diseases such as breast cancer, the most common cancer among women in MRCs. The Middle Resource Scenarios Working Group of the BHGI 2010 Global Summit met to identify common issues and obstacles to breast cancer detection, diagnosis and treatment in MRCs. They concluded that breast cancer early detection programs continue to be important, should include clinical breast examination (CBE) with or without mammography, and should be coupled with active awareness programs. Mammographic screening is usually opportunistic and early detection programs are often hampered by logistical and financial problems, as well as socio-cultural barriers, despite improved public educational efforts. Although multidisciplinary services for treatment are available, geographical and economic limitations to these services can lead to an inequity in health care access. Without adequate health insurance coverage, limited personal finances can be a significant barrier to care for many patients. Despite the improved availability of services (surgery, pathology, radiology and radiotherapy), quality assurance programs remain a challenge. Better access to anticancer drugs is needed to improve outcomes, as are rehabilitation programs for survivors. Focused and sustained government health care financing in MRCs is needed to improve early detection and treatment of breast cancer. (C) 2011 Elsevier Ltd. All rights reserved.

Revista



Revista ISSN
Breast 0960-9776

Métricas Externas



PlumX Altmetric Dimensions

Muestra métricas de impacto externas asociadas a la publicación. Para mayor detalle:

Disciplinas de Investigación



WOS
Obstetrics & Gynecology
Oncology
Scopus
Surgery
Oncology
Cancer Research
SciELO
Sin Disciplinas

Muestra la distribución de disciplinas para esta publicación.

Publicaciones WoS (Ediciones: ISSHP, ISTP, AHCI, SSCI, SCI), Scopus, SciELO Chile.

Colaboración Institucional



Muestra la distribución de colaboración, tanto nacional como extranjera, generada en esta publicación.


Autores - Afiliación



Ord. Autor Género Institución - País
1 Yip, Cheng-Har - Univ Malaya - Malasia
University of Malaya Medical Centre - Malasia
2 Cazap, Eduardo Hombre SLACOM Soc Latinoamer & Caribe Oncol Med - Argentina
SLACOM-Sociedad Latinoamericana y del Caribe de Oncología Médica - Argentina
3 Anderson, Benjamin O. Hombre UNIV WASHINGTON - Estados Unidos
University of Washington, Seattle - Estados Unidos
Fred Hutchinson Cancer Research Center - Estados Unidos
University of Washington - Estados Unidos
4 Bright, Kristin L. Mujer NYU - Estados Unidos
NYU Grossman School of Medicine - Estados Unidos
5 Caleffi, Maira Mujer Hosp Moinhos Venta - Brasil
Hospital Moinhos de Vento - Brasil
6 Cardoso, Fatima Mujer European Sch Oncol - Italia
Champalimaud Canc Ctr - Portugal
European School of Oncology - Italia
Champalimaud Cancer Center - Portugal
7 Elzawawy, Ahmed M. Hombre ICEDOC - Egipto
International Campaign for Establishment and Development of Oncology Centers (ICEDOC) - Egipto
8 Harford, Joe B. Hombre NCI - Estados Unidos
National Cancer Institute - Estados Unidos
National Cancer Institute (NCI) - Estados Unidos
9 Krygier, Gabriel D. Hombre Acad Univ Clin Hosp Montevideo - Uruguay
Natl Breast Canc Program - Uruguay
Hospital de Clínicas Dr. Manuel Quíntela - Uruguay
National Breast Cancer Program - Uruguay
10 Masood, Shahla Mujer UNIV FLORIDA - Estados Unidos
University of Florida College of Medicine - Estados Unidos
11 Murillo, Raul Hombre Inst Nacl Cancerol Colombia - Colombia
Instituto Nacional de Cancerología de Colombia - Canadá
12 Muse, Ignacio M. Hombre Natl Canc Program - Uruguay
National Breast Cancer Program - Uruguay
Natl Breast Canc Program - Uruguay
13 Otero, Isabel V. Mujer NCI - Estados Unidos
National Cancer Institute - Estados Unidos
National Cancer Institute (NCI) - Estados Unidos
14 Passman, Leigh J. Mujer Instituto Nacional del Cancer - Brasil
Instituto Nacional de Câncer - Brasil
National Cancer Institute - Estados Unidos
National Cancer Institute (NCI) - Brasil
15 SANTINI-RODRIGUES, LUIZ ANTONIO - Instituto Nacional del Cancer - Brasil
Instituto Nacional de Câncer - Brasil
National Cancer Institute - Estados Unidos
National Cancer Institute (NCI) - Brasil
16 Ferreira da Silva, Ronaldo Correa Hombre Instituto Nacional del Cancer - Brasil
Shanghai Municipal Ctr Dis Control & Prevent - China
Instituto Nacional de Câncer - Brasil
Shanghai Municipal Center for Disease Control and Prevention - China
16 da Silva, Ronaldo Corrêa Ferreira Hombre Instituto Nacional de Câncer - Brasil
Shanghai Municipal Center for Disease Control and Prevention - China
National Cancer Institute - Estados Unidos
National Cancer Institute (NCI) - Brasil
17 Thomas, David B. Hombre Fred Hutchinson Cancer Research Center - Estados Unidos
18 TORRES-DIAZ, MARIA SOLEDAD Mujer Clínica Las Condes - Chile
19 Zhengs, Ying - Shanghai Municipal Ctr Dis Control & Prevent - China
Shanghai Municipal Center for Disease Control and Prevention - China
20 Khaled, Hussein M. Hombre Cairo Univ - Egipto
Cairo University - Egipto

Muestra la afiliación y género (detectado) para los co-autores de la publicación.

Financiamiento



Fuente
National Institutes of Health
GlaxoSmithKline
National Cancer Institute
U.S. Department of Health and Human Services
GSK
European School of Oncology
Sanofi-Aventis
U.S. Department of Defense
Pan American Health Organization
Breast Cancer Research Foundation
Centers for Disease Control and Prevention
GlaxoSmithKline Australia
GE Healthcare
UICC
Susan G. Komen for the Cure
Office of Research on Women’s Health
Bayer Sherling Pharma
Breast Cancer Research Foundation (BCRF)
Breast Health Global Initiative (BHGI)
Sheikh Mohammed Hussein Al-Amoudi Center of Excellence in Breast Cancer
U.S. Office of Science Planning and Assessment, National Cancer Institute
U.S. Office of Research on Women's Health, National Institutes of Health
U.S. Office of Women's Health, Department of Health and Human Services
U.S. Centers for Disease Control and Prevention
American Society of Clinical Oncology
Fred Hutchinson Cancer Research Center
Susan G. Komen for the CureRegistered
LIVESTRONG
ASCO
U.S. Office of International Affairs, National Cancer Institute
ESMO
U.S. Office of International Affairs
U.S. Department of Defense Breast Cancer Research Program Center of Excellence
International Union Against Cancer
European Society for Medical Oncology
Office of Science Planning and Assessment
Connecticut Breast Health Initiative
Office of Women’s Health
Office of Research on Women's Health
Office of International Affairs
Breast Health Global Initiative
Office of Women's Health
GE Healthcare and Sanofi-Aventis

Muestra la fuente de financiamiento declarada en la publicación.

Agradecimientos



Agradecimiento
BHGI received (2010 Global Summit) grants and contributions from Fred Hutchinson Cancer Research Center; Susan G. Komen for the Cure (R) (Grant Award SG09-0605-01-BHGI); U.S. Office of International Affairs, National Cancer Institute; European School of Oncology; Pan American Health Organization; Sheikh Mohammed Hussein Al-Amoudi Center of Excellence in Breast Cancer; American Society of Clinical Oncology; LIVESTRONG; U.S. Centers for Disease Control and Prevention; U.S. Office of Women's Health, Department of Health and Human Services; U.S. Office of Science Planning and Assessment, National Cancer Institute; U.S. Office of Research on Women's Health, National Institutes of Health and unrestricted educational grants from GE Healthcare and Sanofi-Aventis.
BOA received funding from Breast Health Global Initiative (BHGI) , EC received consultancy funding from Bayer Sherling Pharma, grants from Breast Cancer Research Foundation (BCRF) and Poniard Pharmaceuticals, was on the speakers bureaus for Bayer and Bristol Meyers Squibb, and received travel expenses from ASCO, UICC, ESMO, and BCRF; CHY was on an expert panel and received research funding from GSK and was on the speakers bureaus for Sanofi-Aventis and Roche. DBT has received funding from BHGI for travel. KB received funding from U.S. Department of Defense Breast Cancer Research Program Center of Excellence ( #W81XWH-04-1-0905 ). All other authors and working group members reported no conflict of interest.

Muestra la fuente de financiamiento declarada en la publicación.